xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06025227</url>
    </required_header>
    <id_info>
      <org_study_id>C504</org_study_id>
      <nct_id>NCT06025227</nct_id>
    </id_info>
    <brief_title>Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.</brief_title>
    <sponsors>
      <lead_sponsor>
        <agency>Pfizer</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>In Expanded Access, treating physicians are the Sponsors</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>Pfizer</source>
    <brief_summary>
      <textblock>
        Provide pre-approval single patient Expanded Access (Compassionate Use) of Etrasimod for&#xD;
        patients.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Expanded Access requests from treating physicians may be submitted to www.pfizercares.com.&#xD;
        Availability will depend on location and country.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Available</overall_status>
    <study_type>Expanded Access</study_type>
    <has_expanded_access>No</has_expanded_access>
    <expanded_access_info>
      <expanded_access_type_individual>Yes</expanded_access_type_individual>
    </expanded_access_info>
    <condition>Colitis, Ulcerative</condition>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Etrasimod</intervention_name>
      <description>tablets</description>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Patient must be intolerant, have a contraindication or had inadequate response to at least&#xD;
          3 therapies available for Ulcerative Colitis (UC) in this country or provide a rationale of&#xD;
          why therapy was not used.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
    </eligibility>
    <overall_contact>
      <last_name>PfizerCares</last_name>
      <email>PfizerCares@Pfizer.com</email>
    </overall_contact>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 29, 2023</study_first_submitted>
    <study_first_submitted_qc>August 29, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 6, 2023</study_first_posted>
    <last_update_submitted>August 29, 2023</last_update_submitted>
    <last_update_submitted_qc>August 29, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 6, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Ulcerative Colitis</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Colitis</mesh_term>
      <mesh_term>Colitis, Ulcerative</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06025227
  org study id: C504
  nct id: NCT06025227
  lead sponsor: 
  collaborator: 
  Provide pre-approval single patient Expanded Access (Compassionate Use) of Etrasimod for
        patients.
  Expanded Access requests from treating physicians may be submitted to www.pfizercares.com.
        Availability will depend on location and country.
  expanded access type individual: Yes
  intervention type: Drug
  intervention name: Etrasimod
  description: tablets
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  last name: PfizerCares
  email: PfizerCares@Pfizer.com
  responsible party type: Sponsor
  mesh term: Colitis
  mesh term: Colitis, Ulcerative